Schroder Investment Management Group
PACB icon

Schroder Investment Management Group’s Pacific Biosciences PACB Stock Holding History

Schroder Investment Management Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-459,830
Closed -$1.72M – 1244
2024
Q1 		$1.72M Sell
459,830
-11,634
-2% -$68.1K ﹤0.01% 941
2023
Q4 		$4.63M Sell
471,464
-182,380
-28% -$1.49M 0.01% 783
2023
Q3 		$5.46M Sell
653,844
-58,573
-8% -$669K 0.01% 735
2023
Q2 		$9.48M Buy
+712,417
New +$8.66M 0.01% 641

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schroder Investment Management Group's PACB Position: Q2 2024 in Review

Schroder Investment Management Group sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 459,830 shares — an estimated $1.72M sold.

Schroder Investment Management Group first reported a position in PACB in Q2 2023 and held it in 4 quarters. The position peaked at $9.48M in Q2 2023. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Schroder Investment Management Group reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Schroder Investment Management Group sold 459,830 Pacific Biosciences shares in Q2 2024, an estimated $1.72M.
  • Schroder Investment Management Group first reported a position in Pacific Biosciences in Q2 2023 and held it in 4 quarters.
  • Schroder Investment Management Group's Pacific Biosciences position peaked at $9.48M in Q2 2023.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Schroder Investment Management Group's 13F filing for Q2 2024, filed 12 Aug 2024.